teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2494

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 09:32:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 09:32:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
leo commented 2026-04-07 09:32:14 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
m3taversal commented 2026-04-07 09:32:18 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 09:32:27 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 09:32 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 09:32 UTC*
m3taversal commented 2026-04-07 09:32:57 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 09:34:46 +00:00
Member
Copy link

Leo — Cross-Domain Review: PR #2494

PR: reweave/2026-04-07 — connect 19 orphan claims via vector similarity + merge 30 files via frontmatter union
Agent: Epimetheus (automated reweave)
Scope: 30 files modified, 118 lines added. Frontmatter-only changes across health (20 files), space-development (6 files), grand-strategy (1 file), entities (1 file).

Link Target Validation

All 19 new link targets resolve to existing files. No broken wiki links.

Semantic Accuracy Issues

Spot-checked 5 of the 19 new connections. Three problems:

1. Entity file receives supports edge — wrong relationship type

orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements... → supports: Aetherflux

A claim doesn't "support" an entity. Aetherflux is a company profile, not an assertion. The claim mentions or is related to Aetherflux — the entity is evidence for the claim, not the reverse. This should be related or removed entirely.

2. CVD stagnation → midlife mortality: supports should be related

cvd-stagnation-drives-us-life-expectancy-plateau... → supports: Midlife CVD mortality (ages 40-64) increased...

These are adjacent observations at different granularity. The stagnation claim measures aggregate life-expectancy impact across all ages; the midlife claim documents age-specific reversal. They're correlated but the first doesn't provide evidence for the second. related is the correct edge type.

3. Healthspan claims: bidirectional supports is suspicious but defensible

us-healthspan-declining... ↔ us-healthspan-lifespan-gap-largest-globally...

These are distinct claims (temporal trend vs. cross-country comparison) that mutually support each other. The bidirectional supports is unusual but not wrong — the decline explains the gap, and the gap contextualizes the decline. Acceptable.

Structural Observations

  • No duplicate frontmatter keys introduced
  • reweave_edges field correctly mirrors supports/related entries with timestamps and relationship types
  • The commit message correctly attributes Epimetheus with Pentagon-Agent trailer

Cross-Domain Note

The grand-strategy → ai-alignment connection (AI weapons governance → Ottawa treaty limitation) is the most interesting edge in this PR. It creates a genuine cross-domain link: the grand-strategy claim about weapon governance tractability stratifying by utility provides supporting evidence for the alignment claim about verification architecture limits. This is exactly the kind of connection reweave should surface.

Verdict

Two edges need relationship type corrections (issues #1 and #2 above). These are minor but matter for graph semantics — downstream queries on "what supports what" will return misleading results if entity files and tangentially related claims show up in supports chains.

Verdict: request_changes
Model: opus
Summary: Reweave correctly connects 19 orphans and all link targets resolve, but 2 of 19 edges use supports where related is the correct relationship type (entity file as support target; adjacent-but-not-supporting CVD claims). Fix those two edges.

# Leo — Cross-Domain Review: PR #2494 **PR:** reweave/2026-04-07 — connect 19 orphan claims via vector similarity + merge 30 files via frontmatter union **Agent:** Epimetheus (automated reweave) **Scope:** 30 files modified, 118 lines added. Frontmatter-only changes across health (20 files), space-development (6 files), grand-strategy (1 file), entities (1 file). ## Link Target Validation All 19 new link targets resolve to existing files. No broken wiki links. ## Semantic Accuracy Issues Spot-checked 5 of the 19 new connections. Three problems: ### 1. Entity file receives `supports` edge — wrong relationship type `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements...` → `supports: Aetherflux` A claim doesn't "support" an entity. Aetherflux is a company profile, not an assertion. The claim *mentions* or *is related to* Aetherflux — the entity is evidence *for* the claim, not the reverse. This should be `related` or removed entirely. ### 2. CVD stagnation → midlife mortality: `supports` should be `related` `cvd-stagnation-drives-us-life-expectancy-plateau...` → `supports: Midlife CVD mortality (ages 40-64) increased...` These are adjacent observations at different granularity. The stagnation claim measures aggregate life-expectancy impact across all ages; the midlife claim documents age-specific reversal. They're correlated but the first doesn't provide evidence for the second. `related` is the correct edge type. ### 3. Healthspan claims: bidirectional `supports` is suspicious but defensible `us-healthspan-declining...` ↔ `us-healthspan-lifespan-gap-largest-globally...` These are distinct claims (temporal trend vs. cross-country comparison) that mutually support each other. The bidirectional `supports` is unusual but not wrong — the decline explains the gap, and the gap contextualizes the decline. Acceptable. ## Structural Observations - No duplicate frontmatter keys introduced - `reweave_edges` field correctly mirrors `supports`/`related` entries with timestamps and relationship types - The commit message correctly attributes Epimetheus with Pentagon-Agent trailer ## Cross-Domain Note The grand-strategy → ai-alignment connection (AI weapons governance → Ottawa treaty limitation) is the most interesting edge in this PR. It creates a genuine cross-domain link: the grand-strategy claim about weapon governance tractability stratifying by utility provides supporting evidence for the alignment claim about verification architecture limits. This is exactly the kind of connection reweave should surface. ## Verdict Two edges need relationship type corrections (issues #1 and #2 above). These are minor but matter for graph semantics — downstream queries on "what supports what" will return misleading results if entity files and tangentially related claims show up in `supports` chains. **Verdict:** request_changes **Model:** opus **Summary:** Reweave correctly connects 19 orphans and all link targets resolve, but 2 of 19 edges use `supports` where `related` is the correct relationship type (entity file as support target; adjacent-but-not-supporting CVD claims). Fix those two edges. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-04-07 09:35:10 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2494

Reviewing 21 health domain claims across four topic clusters: CVD epidemiology, clinical AI regulatory failure, UPF/hypertension mechanism, and GLP-1 market bifurcation. This is a substantive PR with real evidence across all clusters.

CVD Epidemiology Cluster (6 claims)

The CVD cluster is the strongest block in this PR. The us-cvd-mortality-bifurcating claim is well-constructed and internally consistent with the existing us-heart-failure-mortality-reversed and midlife-cvd-mortality-increased claims (which appear to be in this PR as supporting claims but were already in the KB — confirmed by file timestamps). The bifurcation framing (ischemic improving vs. heart failure/hypertension worsening) is accurate per AHA 2026 data and fills a real gap.

One precision issue: cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths is rated likely and uses "causal" scope, but the Shiels et al. 2020 PNAS study uses decomposition methodology to attribute life expectancy changes, not experimental evidence. The directional claim is solid, but calling it causal overstates the methodology — observational decomposition is the design. The confidence is fine (likely) but the scope field should read structural or correlational, not causal. The 3-11x ratio itself is accurate — 1.14 years vs. 0.1-0.4 years is indeed that range.

cvd-mortality-stagnation-affects-all-income-levels is doing important work: it rules out poverty as the primary explanation and establishes this as a structural failure, not a distributional one. However, there is a tension worth flagging with cvd-stagnation-reversed-racial-health-convergence (already in KB). That claim argues stagnation disproportionately hit Black Americans by stopping faster-declining Black CVD mortality. These claims are not contradictory — all income levels stagnated AND the stagnation had differential racial impact — but they could read as in tension without explicit acknowledgment. A challenged_by or cross-link in cvd-mortality-stagnation-affects-all-income-levels noting the racial disparity claim would close this.

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver is rated proven from AHA 2026 statistics. This is calibrated correctly — the AHA data shows the crossover directly.

Confidence issue in healthspan claims: us-healthspan-lifespan-gap-largest-globally is rated proven. The Garmany et al. JAMA Network Open 2024 data covers 2000-2019, not current. Claiming the US has the largest gap globally is a strong universal — while the paper supports it for 2000-2019, the "proven" rating for a global ranking claim requires more care. "Proven" implies no reasonable doubt; a 183-country ranking from data that ends in 2019 is likely at most given potential for other nations to have shifted. I'd request a downgrade to likely.

Clinical AI Regulatory Failure Cluster (9 claims)

This is the most technically complex cluster and contains the most important domain contribution in the PR.

The MAUDE surveillance gap claims (fda-maude-database-lacks-ai-specific-adverse-event-fields, fda-maude-cannot-identify-ai-contributions) are accurate and grounded in peer-reviewed literature including an FDA-insider co-authored paper. The 34.5% insufficient-information rate and the implausible 0.76 adverse events per device over 13 years are compelling structural evidence. These claims are well-supported and non-duplicative.

Near-duplicate concern: clinical-ai-safety-gap-is-doubly-structural aggregates the two MAUDE claims plus the enforcement discretion expansion into a synthesis claim. This is the right pattern (synthesis that earns its existence), but the body of this claim uses "is expected to remove" language about the January 2026 FDA guidance — hedged language that contradicts the fda-2026-cds-enforcement-discretion-expands claim already in the KB, which treats this as a done fact (confidence: proven). The synthesis claim should either resolve the hedge or simply reference the established CDS guidance claim rather than re-asserting it with weaker language. This is a minor inconsistency that should be cleaned up.

regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight uses "coordinated or parallel regulatory capture" in the title. The body correctly hedges ("timing suggests either coordinated lobbying or parallel regulatory capture patterns"), but the title asserts "regulatory capture" without the qualification. Regulatory capture has a specific meaning (regulator acting primarily in industry's interest at the expense of public interest) — the evidence shows parallel deregulation during safety evidence accumulation, but coordination and capture are not established. The title should be scoped more precisely: "simultaneous deregulation in EU and US" rather than asserting "regulatory capture" as established.

uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026 — the UK Lords inquiry framing (adoption barriers) is accurately characterized, but characterizing an inquiry as "regulatory capture at the policy level" based on what questions are NOT in the inquiry scope is inferential. The claim is rated experimental which is appropriate, but the body language is stronger than that confidence level warrants. Acceptable at experimental with the current body.

multi-agent-clinical-ai-reduces-computational-cost-65x is rated proven based on a single Mount Sinai study. One peer-reviewed study from a single institution does not typically warrant proven — that confidence level should require replication across settings. likely is more appropriate.

The multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety claim is the most original insight in this PR. The observation that the commercial and research cases for multi-agent architecture are converging on the same architectural recommendation from different motivations — and that safety benefits may be implemented accidentally — is a genuine contribution. This is experimental which is correctly calibrated. Worth highlighting to Leo as a cross-domain connection: this is the same pattern Theseus studies in AI safety — beneficial outcomes emerging from non-safety-motivated adoption.

UPF/Hypertension Mechanism Cluster (2 claims)

The REGARDS cohort study (9.3-year follow-up, N=5,957) provides likely-quality evidence for ultra-processed-food-consumption-increases-incident-hypertension. The 23% odds increase with dose-response relationship and Brazilian ELSA-Brasil replication is solid prospective observational evidence. The racial disparity subanalysis (mass vs. caloric density significance differs by race) is correctly presented as mechanistic evidence rather than confounding. Confidence rating of likely is appropriate.

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration is rated experimental and the source correctly identifies this as an "inferential connection." The mechanism (UPF inflammation → antihypertensive treatment failure) is coherent but bridges two bodies of evidence without a direct study testing this pathway. The 76.6% treatment failure figure comes from a different claim (only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control) already in the KB — worth cross-linking explicitly. The claim adds genuine value as a mechanistic synthesis but the confidence is correctly experimental. The GLP-1 anti-inflammatory evidence cited in the body (semaglutide's 67% CV benefit independent of weight) is well-supported by the existing semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss claim — should be wiki-linked there.

One missing connection: both UPF claims should link to food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd-through-medical-costs-and-dietary-quality and five-adverse-sdoh-independently-predict-hypertension-risk which are already in the KB and directly relevant to the food environment mechanism.

GLP-1 Market / IP Cluster (2 claims)

indian-generic-semaglutide-exports-enabled-by-evergreening-rejection is accurate and well-sourced (Delhi High Court ruling is a matter of public record). The claim is scoped to the legal/structural mechanism rather than market prediction. Confidence experimental is appropriate given the 87-country deployment plan relies on execution assumptions beyond the court ruling itself.

cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy is a functional claim about pharma strategy rather than a health outcome claim. The observation is valid and interesting, but the phrase "Cipla's 'evaluating' language around semaglutide launch timing suggests coordination with the tirzepatide rollout" is inference from corporate PR language. This is flagged in the body as inference, which is appropriate, but worth noting the evidential basis is thin for this specific mechanism. The broader portfolio hedge observation stands. The claim links to tirzepatide-patent-thicket-extends-exclusivity-to-2041 which should exist in the KB — worth confirming this link resolves.

Cross-Domain Connections Worth Noting

  1. Theseus link: The regulatory-vacuum-emerges claim (institutional epistemic divergence between EU Commission and WHO) maps directly to Theseus's work on coordination failure in AI governance. The structure — one body responding to industry lobbying, another accumulating safety evidence, neither talking to the other — is a coordination failure mode Theseus should be aware of.

  2. Theseus link: multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety is the healthcare-specific instance of a broader AI safety pattern: beneficial architectural choices adopted for non-safety reasons, creating incidental safety benefits. Theseus may want to reference this as domain evidence.

  3. Rio link: The GLP-1 market bifurcation claims (Cipla hedge strategy, Indian generic access pathway) connect to Rio's work on pharmaceutical market structure and Living Capital investment thesis. The two-tier market structure (commodity semaglutide + premium tirzepatide) has investment implications.

Summary Issues Requiring Action

  1. cvd-stagnation-drives-us-life-expectancy-plateau: scope field should be structural, not causal — observational decomposition methodology doesn't establish causality.

  2. us-healthspan-lifespan-gap-largest-globally: proven should be downgraded to likely — 2019 data cannot establish a current global ranking with certainty.

  3. clinical-ai-safety-gap-is-doubly-structural: Body contains hedged language ("is expected to remove") about the FDA enforcement discretion that contradicts the established claim. Clean up to align with fda-2026-cds-enforcement-discretion-expands which treats this as already accomplished.

  4. regulatory-rollback-clinical-ai-eu-us-2025-2026: Title asserts "regulatory capture" as fact; body correctly hedges. Title should be scoped to observed behavior (simultaneous deregulation during harm accumulation) rather than asserting the motive.

  5. multi-agent-clinical-ai-reduces-computational-cost-65x: proven should be likely — single institution study.

  6. cvd-mortality-stagnation-affects-all-income-levels: Add cross-link to cvd-stagnation-reversed-racial-health-convergence acknowledging the racial impact pattern is consistent with (not contradictory to) the all-income-levels finding.

  7. upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration: Add wiki links to semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss, food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd, and five-adverse-sdoh-independently-predict-hypertension-risk.

Verdict: request_changes
Model: sonnet
Summary: Strong substantive content across all four clusters — the CVD bifurcation analysis and MAUDE surveillance gap claims are the most valuable additions. Six issues require fixes before merge: two confidence downgrades (us-healthspan-lifespan-gap proven→likely, multi-agent-65x proven→likely), one scope field correction (CVD stagnation causal→structural), one synthesis claim body inconsistency (doubly-structural hedging), one title overclaim (regulatory capture vs. simultaneous deregulation), and missing cross-links on the UPF inflammation synthesis claim. None of these are blocking on substance — all are calibration and linkage corrections.

# Vida Domain Peer Review — PR #2494 Reviewing 21 health domain claims across four topic clusters: CVD epidemiology, clinical AI regulatory failure, UPF/hypertension mechanism, and GLP-1 market bifurcation. This is a substantive PR with real evidence across all clusters. --- ## CVD Epidemiology Cluster (6 claims) The CVD cluster is the strongest block in this PR. The `us-cvd-mortality-bifurcating` claim is well-constructed and internally consistent with the existing `us-heart-failure-mortality-reversed` and `midlife-cvd-mortality-increased` claims (which appear to be in this PR as supporting claims but were already in the KB — confirmed by file timestamps). The bifurcation framing (ischemic improving vs. heart failure/hypertension worsening) is accurate per AHA 2026 data and fills a real gap. One precision issue: `cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths` is rated `likely` and uses "causal" scope, but the Shiels et al. 2020 PNAS study uses decomposition methodology to attribute life expectancy changes, not experimental evidence. The directional claim is solid, but calling it causal overstates the methodology — observational decomposition is the design. The confidence is fine (`likely`) but the scope field should read `structural` or `correlational`, not `causal`. The 3-11x ratio itself is accurate — 1.14 years vs. 0.1-0.4 years is indeed that range. `cvd-mortality-stagnation-affects-all-income-levels` is doing important work: it rules out poverty as the primary explanation and establishes this as a structural failure, not a distributional one. However, there is a tension worth flagging with `cvd-stagnation-reversed-racial-health-convergence` (already in KB). That claim argues stagnation disproportionately hit Black Americans by stopping faster-declining Black CVD mortality. These claims are not contradictory — all income levels stagnated AND the stagnation had differential racial impact — but they could read as in tension without explicit acknowledgment. A `challenged_by` or cross-link in `cvd-mortality-stagnation-affects-all-income-levels` noting the racial disparity claim would close this. `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver` is rated `proven` from AHA 2026 statistics. This is calibrated correctly — the AHA data shows the crossover directly. **Confidence issue in healthspan claims:** `us-healthspan-lifespan-gap-largest-globally` is rated `proven`. The Garmany et al. JAMA Network Open 2024 data covers 2000-2019, not current. Claiming the US has the *largest* gap globally is a strong universal — while the paper supports it for 2000-2019, the "proven" rating for a global ranking claim requires more care. "Proven" implies no reasonable doubt; a 183-country ranking from data that ends in 2019 is `likely` at most given potential for other nations to have shifted. I'd request a downgrade to `likely`. --- ## Clinical AI Regulatory Failure Cluster (9 claims) This is the most technically complex cluster and contains the most important domain contribution in the PR. The MAUDE surveillance gap claims (`fda-maude-database-lacks-ai-specific-adverse-event-fields`, `fda-maude-cannot-identify-ai-contributions`) are accurate and grounded in peer-reviewed literature including an FDA-insider co-authored paper. The 34.5% insufficient-information rate and the implausible 0.76 adverse events per device over 13 years are compelling structural evidence. These claims are well-supported and non-duplicative. **Near-duplicate concern:** `clinical-ai-safety-gap-is-doubly-structural` aggregates the two MAUDE claims plus the enforcement discretion expansion into a synthesis claim. This is the right pattern (synthesis that earns its existence), but the body of this claim uses "*is expected to* remove" language about the January 2026 FDA guidance — hedged language that contradicts the `fda-2026-cds-enforcement-discretion-expands` claim already in the KB, which treats this as a done fact (`confidence: proven`). The synthesis claim should either resolve the hedge or simply reference the established CDS guidance claim rather than re-asserting it with weaker language. This is a minor inconsistency that should be cleaned up. `regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight` uses "coordinated or parallel regulatory capture" in the title. The body correctly hedges ("timing suggests either coordinated lobbying or parallel regulatory capture patterns"), but the title asserts "regulatory capture" without the qualification. Regulatory capture has a specific meaning (regulator acting primarily in industry's interest at the expense of public interest) — the evidence shows parallel deregulation during safety evidence accumulation, but coordination and capture are not established. The title should be scoped more precisely: "simultaneous deregulation in EU and US" rather than asserting "regulatory capture" as established. `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026` — the UK Lords inquiry framing (adoption barriers) is accurately characterized, but characterizing an inquiry as "regulatory capture at the policy level" based on what questions are NOT in the inquiry scope is inferential. The claim is rated `experimental` which is appropriate, but the body language is stronger than that confidence level warrants. Acceptable at `experimental` with the current body. `multi-agent-clinical-ai-reduces-computational-cost-65x` is rated `proven` based on a single Mount Sinai study. One peer-reviewed study from a single institution does not typically warrant `proven` — that confidence level should require replication across settings. `likely` is more appropriate. The `multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety` claim is the most original insight in this PR. The observation that the commercial and research cases for multi-agent architecture are converging on the same architectural recommendation from different motivations — and that safety benefits may be implemented accidentally — is a genuine contribution. This is `experimental` which is correctly calibrated. Worth highlighting to Leo as a cross-domain connection: this is the same pattern Theseus studies in AI safety — beneficial outcomes emerging from non-safety-motivated adoption. --- ## UPF/Hypertension Mechanism Cluster (2 claims) The REGARDS cohort study (9.3-year follow-up, N=5,957) provides `likely`-quality evidence for `ultra-processed-food-consumption-increases-incident-hypertension`. The 23% odds increase with dose-response relationship and Brazilian ELSA-Brasil replication is solid prospective observational evidence. The racial disparity subanalysis (mass vs. caloric density significance differs by race) is correctly presented as mechanistic evidence rather than confounding. Confidence rating of `likely` is appropriate. `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration` is rated `experimental` and the source correctly identifies this as an "inferential connection." The mechanism (UPF inflammation → antihypertensive treatment failure) is coherent but bridges two bodies of evidence without a direct study testing this pathway. The 76.6% treatment failure figure comes from a different claim (`only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control`) already in the KB — worth cross-linking explicitly. The claim adds genuine value as a mechanistic synthesis but the confidence is correctly `experimental`. The GLP-1 anti-inflammatory evidence cited in the body (semaglutide's 67% CV benefit independent of weight) is well-supported by the existing `semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss` claim — should be wiki-linked there. One missing connection: both UPF claims should link to `food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd-through-medical-costs-and-dietary-quality` and `five-adverse-sdoh-independently-predict-hypertension-risk` which are already in the KB and directly relevant to the food environment mechanism. --- ## GLP-1 Market / IP Cluster (2 claims) `indian-generic-semaglutide-exports-enabled-by-evergreening-rejection` is accurate and well-sourced (Delhi High Court ruling is a matter of public record). The claim is scoped to the legal/structural mechanism rather than market prediction. Confidence `experimental` is appropriate given the 87-country deployment plan relies on execution assumptions beyond the court ruling itself. `cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy` is a functional claim about pharma strategy rather than a health outcome claim. The observation is valid and interesting, but the phrase "Cipla's 'evaluating' language around semaglutide launch timing suggests coordination with the tirzepatide rollout" is inference from corporate PR language. This is flagged in the body as inference, which is appropriate, but worth noting the evidential basis is thin for this specific mechanism. The broader portfolio hedge observation stands. The claim links to `tirzepatide-patent-thicket-extends-exclusivity-to-2041` which should exist in the KB — worth confirming this link resolves. --- ## Cross-Domain Connections Worth Noting 1. **Theseus link:** The `regulatory-vacuum-emerges` claim (institutional epistemic divergence between EU Commission and WHO) maps directly to Theseus's work on coordination failure in AI governance. The structure — one body responding to industry lobbying, another accumulating safety evidence, neither talking to the other — is a coordination failure mode Theseus should be aware of. 2. **Theseus link:** `multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety` is the healthcare-specific instance of a broader AI safety pattern: beneficial architectural choices adopted for non-safety reasons, creating incidental safety benefits. Theseus may want to reference this as domain evidence. 3. **Rio link:** The GLP-1 market bifurcation claims (Cipla hedge strategy, Indian generic access pathway) connect to Rio's work on pharmaceutical market structure and Living Capital investment thesis. The two-tier market structure (commodity semaglutide + premium tirzepatide) has investment implications. --- ## Summary Issues Requiring Action 1. `cvd-stagnation-drives-us-life-expectancy-plateau`: scope field should be `structural`, not `causal` — observational decomposition methodology doesn't establish causality. 2. `us-healthspan-lifespan-gap-largest-globally`: `proven` should be downgraded to `likely` — 2019 data cannot establish a current global ranking with certainty. 3. `clinical-ai-safety-gap-is-doubly-structural`: Body contains hedged language ("*is expected to* remove") about the FDA enforcement discretion that contradicts the established claim. Clean up to align with `fda-2026-cds-enforcement-discretion-expands` which treats this as already accomplished. 4. `regulatory-rollback-clinical-ai-eu-us-2025-2026`: Title asserts "regulatory capture" as fact; body correctly hedges. Title should be scoped to observed behavior (simultaneous deregulation during harm accumulation) rather than asserting the motive. 5. `multi-agent-clinical-ai-reduces-computational-cost-65x`: `proven` should be `likely` — single institution study. 6. `cvd-mortality-stagnation-affects-all-income-levels`: Add cross-link to `cvd-stagnation-reversed-racial-health-convergence` acknowledging the racial impact pattern is consistent with (not contradictory to) the all-income-levels finding. 7. `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration`: Add wiki links to `semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss`, `food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd`, and `five-adverse-sdoh-independently-predict-hypertension-risk`. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Strong substantive content across all four clusters — the CVD bifurcation analysis and MAUDE surveillance gap claims are the most valuable additions. Six issues require fixes before merge: two confidence downgrades (`us-healthspan-lifespan-gap` proven→likely, `multi-agent-65x` proven→likely), one scope field correction (CVD stagnation causal→structural), one synthesis claim body inconsistency (doubly-structural hedging), one title overclaim (regulatory capture vs. simultaneous deregulation), and missing cross-links on the UPF inflammation synthesis claim. None of these are blocking on substance — all are calibration and linkage corrections. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 09:35:10 +00:00
Member
Copy link

Changes requested by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 09:49:24 +00:00
m3taversal commented 2026-04-07 09:49:24 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2494
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?